HUMAN PAPILLOMAVIRUS VACCINATION
RECOMMENDATIONS OF THE EXPERT COMMITTEE ON IMMUNISATION
1. Among Singapore women, cervical cancer is the sixth most frequent cancer and eight most frequent cause of cancer death. Cervical cancer is caused by the Human Papilloma Virus (HPV).
2. MOH's Expert Committee on Immunisation (ECI) has recommended that HPV vaccines, which are clinically safe and effective, be included into the National Immunisation Programme (NCIP) for females, in order to prevent clinical cancer. MOH has accepted the ECI's recommendation.
3. There are currently 2 vaccines approved in Singapore. The quadrivalent HPV vaccine (marketed by GARDASIL by Merck) and bivalent HPV (marketed as CERVARIX by GlaxoSmithKline) both protect against HPV type 16 and 18, which are responsible for about 70% of cervical cancer. In addition, the quadrivalent vaccine protects against types 6 and 11, which cause genital warts.
Recommendations of the ECI
4. The ECI has recommended that HPV vaccines be used by females in the age-ranged as specified by the manufacturers (between 9 and 26 years) as the preventive measure against cervical cancer.
5. For full benefit, the vaccine should be given before the onset of sexual activity, as it does not protect against pre-existing HPV infection. However, females who are sexually active can still be vaccinated, as the risk of acquiring HPV infection would continue as long as they are sexually active.
6. The ECI recommended that even after HPV vaccination, all sexually active women aged 25 to 69 years should continue to have regular Pap Smears. This is because HPV vaccination does not protect against all types of cancer-causing HPV.
7. Vaccination in males is not recommended.
USE OF MEDISAVE FOR HPV VACCINATION
8. MOH will allow Medisave to be used to pay for HPV vaccination, like the Pneumococcal and Hepatitis vaccinations.
9. MOH will extend the $300 Medisave annual withdrawal limit that covers vaccinations and outpatient treatment under the Medisave Chronic Disease Management Programme (CDMP) to cover HPV vaccinations for females aged 9-26 years with effect 1 Nov 2010.
10. From 1 Nov 2010, members would thus be able to utilize up to $300 per Medisave account per calendar year for the following vaccinations and treatments:
a) HPV vaccinations for females aged 9-26 years (for vaccinations received on or after 1 Nov 2010)
Laser Vaginal Rejuvenation ® in LA Times
Links to other medical websites for suggested reading
Visit Dr.Matlock's Website
For your reference & reading -